BTIG analyst Thomas Shrader initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $15 price target The company is taking a multi-pronged approach by improving central nervous system delivery of agents with established antitumor activity such as temozolomide and also by developing novel agents active against hard-to-treat CNS tumors, the analyst tells investors. The key catalysts for the stock are incremental data sets supporting activity of its two lead drugs in difficult-to-treat patients expected later in 2026 and 2027, the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc CEO Increases Stake Amid Advancing CNS Cancer Programs
- NeOnc Technologies files to sell 680,558 shares of common stock for holders
- NeOnc Technologies Launches $75 Million ATM Equity Program
- NeOnc Technologies announces $75M at the market equity program
- NeOnc Technologies Reports Q4 Results and Trial Progress